PMID- 37205188
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230522
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 13
DP  - 2023
TI  - Identification of a seven-lncRNAs panel that serves as a prognosis predictor and 
      contributes to the malignant progression of laryngeal squamous cell carcinoma.
PG  - 1106249
LID - 10.3389/fonc.2023.1106249 [doi]
LID - 1106249
AB  - BACKGROUND: Laryngeal squamous cell carcinoma (LSCC) is one of the most frequent 
      head and neck cancers worldwide. Long non-coding RNAs (lncRNAs) play a critical 
      role in tumorigenesis. However, the clinical significance of lncRNAs in LSCC 
      remains largely unknown. METHODS: In this study, transcriptome sequencing was 
      performed on 107 LSCC and paired adjacent normal mucosa (ANM) tissues. 
      Furthermore, RNA expression and clinical data of 111 LSCC samples were obtained 
      from The Cancer Genome Atlas (TCGA) database. Bioinformatics analysis were 
      performed to construct a model for predicting the overall survival (OS) of LSCC 
      patients. Moreover, we investigated the roles of lncRNAs in LSCC cells through 
      loss-of-function experiments. RESULTS: A seven-lncRNAs panel including 
      ENSG00000233397, BARX1-DT, LSAMP-AS1, HOXB-AS4, MNX1-AS1, LINC01385, and 
      LINC02893 was identified. The Kaplan-Meier analysis demonstrated that the 
      seven-lncRNAs panel was significantly associated with OS (HR:6.21 [3.27-11.81], 
      p-value<0.0001), disease-specific survival (DSS) (HR:4.34 [1.83-10.26], 
      p-value=0.0008), and progression-free interval (PFI) (HR:3.78 [1.92-7.43], 
      p-value=0.0001). ROC curves showed the seven-lncRNAs panel predicts OS with good 
      specificity and sensitivity. Separately silencing the seven lncRNAs inhibited the 
      proliferation, migration, and invasion capacity of LSCC cells. CONCLUSION: 
      Collectively, this seven-lncRNAs panel is a promising signature for predicting 
      the prognosis of LSCC patients, and these lncRNAs could serve as potential 
      targets for LSCC treatment.
CI  - Copyright (c) 2023 Zheng, Gao, Zhang, Xue, Mijiti, Guo, Wusiman, Wang, Zeng, Xue, 
      Guo, An and Wu.
FAU - Zheng, Xiwang
AU  - Zheng X
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, Shanxi, China.
AD  - Shanxi Province Clinical Medical Research Center for Precision Medicine of Head 
      and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 
      China.
FAU - Gao, Wei
AU  - Gao W
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Otolaryngology 
      Hospital, Shenzhen, Guangdong, China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Otolaryngology Hospital, Shenzhen, Guangdong, China.
FAU - Zhang, Zhe
AU  - Zhang Z
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, Shanxi, China.
AD  - Shenzhen Eye Hospital, Jinan University, Shenzhen Eye Institute, Shenzhen, 
      Guangdong, China.
FAU - Xue, Xuting
AU  - Xue X
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, Shanxi, China.
AD  - Shanxi Province Clinical Medical Research Center for Precision Medicine of Head 
      and Neck Cancer, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, 
      China.
FAU - Mijiti, Maierhaba
AU  - Mijiti M
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Guo, Qingbo
AU  - Guo Q
AD  - Shanxi Key Laboratory of Otorhinolaryngology Head and Neck Cancer, First Hospital 
      of Shanxi Medical University, Taiyuan, Shanxi, China.
FAU - Wusiman, Dilinaer
AU  - Wusiman D
AD  - Department of Head and Neck Surgery, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Otolaryngology Head & Neck Surgery, Southern University of Science 
      and Technology Hospital, Southern University of Science and Technology, Shenzhen, 
      Guangdong, China.
FAU - Zeng, Xianhai
AU  - Zeng X
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Otolaryngology 
      Hospital, Shenzhen, Guangdong, China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Otolaryngology Hospital, Shenzhen, Guangdong, China.
FAU - Xue, Lingbin
AU  - Xue L
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Otolaryngology 
      Hospital, Shenzhen, Guangdong, China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Otolaryngology Hospital, Shenzhen, Guangdong, China.
FAU - Guo, Zekun
AU  - Guo Z
AD  - College of Life Sciences, Northwest A&F University, Yangling, Shaanxi, China.
FAU - An, Changming
AU  - An C
AD  - Department of Head and Neck Surgery, National Cancer Center/National Clinical 
      Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences 
      and Peking Union Medical College, Beijing, China.
FAU - Wu, Yongyan
AU  - Wu Y
AD  - Department of Otolaryngology Head & Neck Surgery, Longgang Otolaryngology 
      Hospital, Shenzhen, Guangdong, China.
AD  - Shenzhen Institute of Otolaryngology & Key Laboratory of Otolaryngology, Longgang 
      Otolaryngology Hospital, Shenzhen, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20230502
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC10188209
OTO - NOTNLM
OT  - biomarker
OT  - laryngeal squamous cell carcinoma
OT  - long non-coding RNA
OT  - oncogene
OT  - prognosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/19 19:14
MHDA- 2023/05/19 19:15
PMCR- 2023/01/01
CRDT- 2023/05/19 13:05
PHST- 2022/12/08 00:00 [received]
PHST- 2023/04/11 00:00 [accepted]
PHST- 2023/05/19 19:15 [medline]
PHST- 2023/05/19 19:14 [pubmed]
PHST- 2023/05/19 13:05 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2023.1106249 [doi]
PST - epublish
SO  - Front Oncol. 2023 May 2;13:1106249. doi: 10.3389/fonc.2023.1106249. eCollection 
      2023.